Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure

Launched by KURSAT GUNDOGAN · Apr 25, 2017

Keywords

ClinConnect Summary

Acute respiratory failure (ARF) is the leading reason for ICU admission in immunocompromised patients. Usual oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.

High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen (FiO2) values of nearly 100%. Physiological benefits of HFNO consist of higher and ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Known immunosuppression defined as haematological malignancy.
• • Need for oxygen therapy defined as with oxygen free arterial blood gas examination one or more of the following: (a) PaO2/FiO2\<300 mmHg (b) PaCO2≤45 mmHg (c) SaO2\<92%
• • Respiratory distress with a respiratory rate \>22/min
• Exclusion Criteria:
• • Refusal of study participation
• • Pregnancy or breastfeeding
• • Hypercapnia with a formal indication for non-invasive mechanical ventilation (NIMV) (PaCO2 ≥ 45 mmHg)
• • Patients whose clinicians have decided on NIMV (Non-Invasive Mechanical Ventilation) and IMV (Invasive Mechanical Ventilation)
• • Haemodynamic instability (mean arterial pressure \<65 mmHg)
• • Vasopressor needs
• • Awareness confusion and disorientation